<DOC>
	<DOCNO>NCT01983787</DOCNO>
	<brief_summary>At Department Infectious Diseases , Aarhus University Hospital , continuous infusion piperacillin/tazobactam period 2 week , use several year patient cystic fibrosis , suffer acute pulmonary exacerbation ( APE ) . It outpatient treatment . To assess efficacy quality treatment , blood test every 3rd day take determine concentration Piperacillin blood-plasma .</brief_summary>
	<brief_title>Pharmacokinetics Piperacillin , Given Continuous Infusion Patients With Cystic Fibrosis</brief_title>
	<detailed_description>Patients cystic fibrosis ( CF ) often colonize multidrug-resistant microorganism , increase risk suboptimal dose antibiotic time minimum inhibitory concentration ( T &gt; MIC ) suboptimal . Continuous infusion beta-lactam antibiotic likely optimize T &gt; MIC intermittent infusion . At Department Infectious Diseases , Aarhus University Hospital , continuous infusion piperacillin/tazobactam period 2 week , use several year patient CF , suffer acute pulmonary exacerbation ( APE ) . It outpatient treatment , patient give 16 g piperacillin per 24 hour . To assess efficacy quality treatment , blood test every 3rd day require monitor blood-plasma concentration piperacillin , well C-reactive protein ( CRP ) white blood cell count ( WBC ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<criteria>Patients Cystic Fibrosis , suffer acute pulmonary exacerbation , treat continuous infusion Piperacillin/Tazobactam period two week . Age 18</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Continuous infusion</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>